293 filings
Page 6 of 15
6-K
oh5m6a9woy8
13 Mar 19
Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th
8:30am
6-K
vbp9m2o7xpb5
21 Feb 19
Current report (foreign)
9:15am
6-K
qxl32hb m4
14 Feb 19
At Market Issuance Sales Agreement
8:13am
6-K
hbzf5znol 1y3kf
14 Feb 19
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
8:05am
6-K
i969ch3c
14 Feb 19
Current report (foreign)
7:55am
6-K
4g2jmlit
8 Feb 19
Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call
8:05am
6-K
k8dtv8s
9 Jan 19
Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office
8:05am
6-K
irycjp6
31 Dec 18
Current report (foreign)
8:00am
6-K
g4e21
20 Dec 18
Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPreĀ® in Patients with Severe Hypertriglyceridemia
8:01am
6-K
qvku7vll2o 3v
14 Nov 18
Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019
8:05am
6-K
3rhu8xey75
14 Nov 18
Current report (foreign)
7:00am
6-K
wj6ck f4tu
7 Nov 18
Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
8:01am
6-K
ztj ec0frreddaxfif
23 Oct 18
Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option
9:21am
6-K
ptfbtk
15 Oct 18
Current report (foreign)
5:15pm
6-K
doqjc8 2aya87euay
11 Oct 18
Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares
7:42am
6-K
0lahzmsqsl1typep
9 Oct 18
Current report (foreign)
5:21pm
6-K
ara5v66ardr09u3
4 Oct 18
Acasti Pharma Prices C$24 Million Underwritten Offering
11:00am
6-K
868lcx92gxenu4sj 06e
4 Oct 18
Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares
11:00am
6-K
sh0re i0b1
3 Oct 18
Acasti Pharma Announces Public Equity Offering
5:15pm
6-K
3neooczdd2157 0uehmk
3 Oct 18
Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares
5:15pm